Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ZQIZB
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
Fluorescent Antibody-Drug Conjugate
|
|||||
| Synonyms |
Fluorescent Antibody-Drug Conjugate (University Of Illinois); alpha-CEA-680-PTX
Click to Show/Hide
|
|||||
| Organization |
University of Illinois
|
|||||
| Drug Status |
Terminated
|
|||||
| Indication |
In total 1 Indication(s)
Pancreatic cancer [ICD11:2C10]
Terminated
|
|||||
| Drug-to-Antibody Ratio |
1.2
|
|||||
| Antibody Name |
Anti-CEA mAb MIC0101
|
Antibody Info | ||||
| Antigen Name |
Pregnancy-specific beta-1-glycoprotein 2 (PSG2)
|
Antigen Info | ||||
| Payload Name |
Paclitaxel
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Amine-reactive NHS ester chemistry was used to conjugate both paclitaxel and DyLight-680-4xPEG to an antibody specific for CEA.
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.